These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00378-9104
Last updated: March 1, 2026
What Is NDC 00378-9104?
NDC 00378-9104 refers to Rituximab, a monoclonal antibody used in oncology and autoimmune diseases. It is marketed under brand names like Rituxan and biosimilar versions. Rituximab is indicated for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and certain vasculitides.
Market Overview
Commercial Landscape
The global monoclonal antibody market was valued at approximately USD 150 billion in 2022.
Rituximab holds an estimated 15-20% share in oncology monoclonal antibody sales.
The drug faces competition from biosimilars introduced since 2017, including Truxima (celltrion), Ruxience (Pfizer), and Zytux (Zytux Biosciences).
As of 2022, biosimilars account for roughly 30% of Rituximab sales globally and are increasing market penetration.
Key Market Drivers
Growing prevalence of non-Hodgkin lymphoma and rheumatoid arthritis increases demand.
Approval of biosimilars reduces costs and expands patient access.
Expanded indications and use in autoimmune diseases drive growth.
Market Challenges
Patent expirations for original formulations from 2016–2018.
Biosimilar price competition reduces revenue for originator.
Reimbursement policies vary across regions, impacting sales.
Regional Analysis
Region
Estimated Market Share (2022)
Key Factors
North America
45%
Largest market; high adoption of biosimilars, reimbursement policies
Europe
35%
High biosimilar uptake; strong regulatory environment
Asia-Pacific
15%
Growing access; emerging biosimilar competition
Rest of World
5%
Limited access; pricing constraints
Price Projections
U.S. Market
Original Rituximab (Brand): Average wholesale price (AWP): USD 4,500–5,000 per vial.
Biosimilars: Priced around USD 2,500–3,500 per vial, representing a 30-50% discount.
Projected Trends (2023–2028):
Biosimilar market share expected to reach 60–70%.
Original brand prices to decline further as biosimilars gain acceptance.
Average vial price for biosimilars may stabilize around USD 2,500 by 2025.
Global Prices
Region
2022 Average Price (USD)
2025 Projected Price (USD)
Comments
U.S.
4,500–5,000
2,500–3,000
Market shift from originator to biosimilar
Europe
4,000–4,500
2,000–2,500
Similar trend; region-specific discounts
Asia-Pacific
3,000–3,500
1,500–2,000
Price reductions driven by biosimilar entry
Price Dynamics
Biosimilar prices are influenced by manufacturing costs, regulatory costs, and market competition.
Price erosion is expected to slow after 2025 as primary biosimilars become established.
Contracting and tendering strategies in healthcare systems may further influence prices.
Competitive Outlook
Biosimilars are expected to account for up to 70% of market volume by 2028.
Key players investing in biosimilar manufacturing and R&D include Celltrion, Pfizer, and Amgen.
Original manufacturer revenue will decline but remains significant in countries with delayed biosimilar adoption.
Regulatory and Policy Factors
The US FDA approved several biosimilars between 2017 and 2022.
The European Medicines Agency (EMA) has broader biosimilar approval pathways since 2005.
Reimbursement and tendering policies tend to favor biosimilar uptake, impacting prices and market share.
Summary of Critical Data Points
Data Point
2022 Value
2023–2028 Outlook
Total market size
USD 150 billion
Growth at 7% CAGR, reaching USD 200 billion
Rituximab share
15–20%
Market share decreasing for originator; rising biosimilars
Biosimilar penetration
30%
60–70% by 2028
Average biosimilar price
USD 2,500–3,500 per vial
Stabilizing around USD 2,500 by 2025
Key Takeaways
The Rituximab market is experiencing a substantial shift driven by biosimilars.
Prices for biosimilars are declining and expected to stabilize within the next three years.
Market share for biosimilars is projected to surpass 60% by 2028, reducing revenue for originators.
Regional policies influence adoption rates and pricing; North America and Europe lead.
Continued R&D and regulatory changes will shape competitive dynamics.
FAQs
What other biosimilar products compete with NDC 00378-9104?
Biosimilars like Truxima, Ruxience, and Zytux compete directly with original Rituximab.
How will biosimilar entry impact pricing?
Biosimilar entry will pressure prices downward, especially in regulated markets, with discounts of up to 50%.
What is the outlook for Rituximab in autoimmune diseases outside oncology?
Growing use in rheumatoid arthritis and vasculitis is expected to sustain demand, but biosimilar competition will influence pricing.
Are there regulatory barriers to biosimilar market entry?
Yes; approval processes vary by region, with more streamlined pathways in the US and Europe.
What emerging factors could alter market projections?
New indications, regulatory changes, or significant price shifts in biosimilars could accelerate or slow market transformation.
References
Statista. (2022). Monoclonal antibody market size and growth projections.
EvaluatePharma. (2022). Oncology biosimilar sales and trends.
EMA. (2022). Biosimilars approval pathways and status updates.
U.S. Food and Drug Administration. (2022). Approved biosimilars for Rituximab.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
